Oil’s Iran Cliffhanger: What To Know And What To Expect
- Analysis
- Barani Krishnan
- 3
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
OMX Copenhagen Pharmaceuticals & Biotechnology PI (CX201030PI)
Comprehensive information about the OMX Copenhagen Pharmaceuticals & Biotechnology PI index. More information is available in the different sections of the OMX Copenhagen Pharmaceuticals & Biotechnology PI page, such as: historical data, charts, technical analysis and others.
Copenhagen
Currency in DKK
7,932.21
0.00(0.00%)
Closed
Day's Range
7,932.21
7,932.21
52 wk Range
7,124.98
12,286.69
Day's Range
7,932.217,932.21
52 wk Range
7,124.9812,286.69
- Prev. Close
- 7,932.21
- Open
- 7,932.21
- 1-Year Change
- -20.68%
- Volume
- 0
- Average Volume (3m)
- -
- Day's Range
- 7,932.21-7,932.21
- 52 wk Range
- 7,124.98-12,286.69
How do you feel today about CX201030PI?
Vote to see community's results!
or- Oil’s Iran Cliffhanger: What To Know And What To Expect
- Analysis
- Barani Krishnan
- 3
| Name | Last | Prev. | High | Low | Chg. % | Vol. | Time | Price | |
|---|---|---|---|---|---|---|---|---|---|
NOVOb Novo Nordisk A/S Class B | 615.40 | 628.90 | 627.60 | 615.40 | -2.15% | 3.41M | 615.40-2.15% | 10/02 | |
HLUNb H Lundbeck B | 42.88 | 42.18 | 43.00 | 41.82 | +1.66% | 582.04K | 42.88+1.66% | 10/02 | |
PEGRP Pharma Equity Group AS | 0.153 | 0.151 | 0.157 | 0.152 | +1.33% | 363.14K | 0.153+1.33% | 10/02 | |
NSISb Novozymes A/S B | 407.30 | 406.00 | 407.40 | 403.60 | +0.32% | 261.73K | 407.30+0.32% | 10/02 | |
BAVA Bavarian Nordic | 173.60 | 175.40 | 178.30 | 173.60 | -1.05% | 216.87K | 173.60-1.05% | 10/02 |
Top Gainers
| Name | Price |
|---|---|
HLUNb H Lundbeck B | 42.88+0.70+1.66% |
PEGRP Pharma Equity AS | 0.153+0.002+1.33% |
HLUNa H Lundbeck B | 34.70+0.20+0.58% |
NSISb Novozymes B | 407.30+1.3+0.32% |
GUBRA Gubra AS | 630.00+2.00+0.32% |
Top Losers
| Name | Price |
|---|---|
BIOPOR BioPorto | 1.506-0.042-2.71% |
NOVOb Novo Nordisk B | 615.40-13.5-2.15% |
STRAP Strategic Partners AS | 775.00-15.90-2.01% |
ZELA Zealand Pharma | 716.00-12.50-1.72% |
GMAB Genmab | 1,367.50-17.5-1.26% |
Tech Titans
Stay ahead of the latest tech trends with our algorithmically-selected portfolio of the 15 top tech stocks each month.
S&P 500 Outperformance+1775.5%
Annualized Return+29.1%
Stocks in this strategy
AAA:AAAA
aaa aaaaaaa aaaa aaaaaaaaaaa
AAA:AAAA
aaa aaaaaaa aaaa aaaaaaaaaaa
AAA:AAAA
aaa aaaaaaa aaaa aaaaaaaaaaa
AAA:AAAA
aaa aaaaaaa aaaa aaaaaaaaaaa
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.